Artemis and Breast Cancer
Artemis and Breast Cancer
1
Discussion.................................................................................................................................................... 31
Future Recommendations .................................................................................................................... 32
Limitations of the Study ........................................................................................................................ 33
References .................................................................................................................................................. 34
Appendix ..................................................................................................................................................... 38
2
Abstract
Antiproliferative effects of the compound, artemisinin, have been observed in several breast
cancer lines. Whole plants extracts appear to be more efficacious than the pure compound in the
treatment of diseases such as malaria. In our studies, MCF-7 breast cancer cells were treated
with purified artemisinin and extracts of the whole plant Artemisia annua to compare the effects.
These results suggest that extracted artemisinin extract contains compounds with antagonistic
3
Acknowledgements
We would like to thank Pam Weathers for donating the plant material used in our experiment.
We would like to further thank Jill Rulfs and Michael Buckholt for their advisory role in this
project.
4
Background
Breast cancer can present itself in a variety of forms which means that treatment must be as
versatile as the disease itself. This project will focus specifically on treating estrogen responsive
estrogen receptor α will be accomplished through treatment of a model cell system (MCF-7) with
pure artemisinin and artemisinin extracts taken from the plant. Artemisinin is a chemical
compound, naturally synthesized by the plant Artemisia annua, found to have antimalarial and
division. This process is known as proliferation. When cancerous cells develop in the tissues of
the breast, the patient has developed the disease breast cancer. Breast cancer can be classified
several different ways depending on location and manner of development, as well as the traits
possessed by the cancerous cells. These cancerous cells are then tested and classified so an
(infiltrating) breast cancer is not confined to a particular location of the breast or body. Instead, it
has broken through the natural tissue barriers to spread throughout the body via the bloodstream
and lymph nodes. Noninvasive (in situ) breast cancer remains in a particular location of the
breast without spreading to other tissues (Henderson, 2003). These two categories can be used to
classify how the other subtypes of breast cancer behave. For example, Ductal Carcinoma begins
5
in the milk ducts and is the most common breast cancer type. Though it originates in the milk
ducts, as the disease progresses in some individuals, it begins to spread to other parts of the body,
or metastasize. This means that this particular form of breast cancer can be classified as invasive
or noninvasive. Lobular carcinoma begins in the glands that produce breast milk (lobules) and is
then transported by the milk ducts. Inflammatory breast cancer is unique in that it starts in the
soft tissues of the breast and blocks the lymph vessels of the skin. This causes the breasts to
become firm, tender, warm, and itchy from the build-up of white blood cells. Papillary
carcinoma is a rare form of breast cancer whose cells are arranged in finger-like projections
known as papules. The final form of breast cancer is called triple negative breast cancer. Breast
cancer cells typically contain receptors for estrogen and progesterone. In addition, “healthy”
breast cancer cells contain receptors for a protein called human epidermal growth factor receptor
2 (HER2). HER2 stimulates normal cell growth in healthy cells. Triple negative breast cancer
occurs when the cancer cells do not contain receptors for progesterone, estrogen, or HER2.
Approximately 10-20% of all breast cancers are triple negative (Henderson, 2003). When breast
cancer cells test negative for all three receptors traditional hormone therapies and medications
are ineffective. Instead, triple negative breast cancer is typically treated through chemotherapy,
Hormone Therapy
Breast cancer cells are typically sensitive to hormones, particularly estrogen. This means that the
cells are activated when hormones bind to receptors on the cell surface. Breast cancer cells that
test positive for estrogen responsiveness are labeled estrogen receptor-positive (ER-positive).
Many ER-positive cell lines are also progesterone receptor-positive (PR-positive). Typically,
progesterone is responsible for the monthly thickening of uterine walls in preparation for
6
pregnancy in women. Hormone therapy works by preventing the body from producing estrogen
and progesterone, the hormones which the tumor cells are most sensitive to. Several treatment
strategies have been developed to treat hormone-sensitive breast cancer including suppressing
estrogen production in the ovaries, preventing estrogen synthesis, and blocking estrogen’s
effects. Understandably, tumors that are not sensitive to hormones are unresponsive to this kind
of treatment.
In premenopausal women, the ovaries are the main source of estrogen. As such, the ovaries are
primarily targeted for reducing or suppressing their function in order to lower estrogen levels.
There are several drugs that suppress the ovaries temporarily using gonadotropin-releasing
Ablation, 2011). Both interfere with pituitary gland signals which target the ovaries and
stimulate estrogen production. Additionally, one of the most extreme processes, called ovarian
ablation, involves surgically removing the ovaries (oophorectomy) or using radiation. Unlike
Other hormone therapies focus on directly blocking estrogen production rather than suppressing
the overall function of the ovaries. Aromatase inhibitors block the activity of aromatase, an
enzyme which the body uses to synthesize estrogen in the ovaries and other tissues. Typically,
this treatment is used in postmenopausal women as premenopausal women produce too much
aromatase for the inhibitors to effectively block (Hormone Therapy for Breast Cancer, 2012).
The final strategy of hormone therapy is to block estrogen’s effects. Selective estrogen
modulators (SERMs) bind to estrogen receptors and prevent estrogen from binding.
Unfortunately, many SERMs act as agonists for estrogen receptors in other tissues. One example
7
of this, tamoxifen, acts antagonistically in breast tissue but agonistically in uterine and bone
Treatment
Typical treatment of early stage breast cancer involves an initial surgery to remove the tumor
cells, followed by an adjuvant therapy. Adjuvant therapy is typically in the form of radiation
therapy, hormone therapy, targeted therapy, or chemotherapy. These adjuvant therapies typically
occur daily for approximately 5 years. Treatment is typically a mix of hormone therapies and
traditionally starts with several years of tamoxifen, a drug which acts antagonistically for
estrogen receptors in breast cancer cells (Hormone Therapy for Breast Cancer, 2012). Treatment
with tamoxifen is followed by treatments with other aromatase inhibitors, or treatment with
tamoxifen is skipped entirely and other aromatase inhibitors are used for the full five years.
Side Effects
Due to tamoxifen’s estrogen-like behavior, premenopausal women treated with it are at a higher
risk for uterine cancer and weaker bones. Tamoxifen also puts patients at risk for stroke, blood
clots, and cataracts (Riggs, 2000). Other SERMs like raloxifene are also known to increase the
risk of blood clots and strokes. Ovarian suppression in patients increases their risk of bone loss
and depression. Ovarian suppression leads to bone loss due to the effects estrogen deficiency has
on osteoclasts. In estrogen deficient environments, osteoclast activity increases and more bone is
reabsorbed (Riggs, 2000). In addition, ovarian suppression can also cause mood swings and
depression. Other aromatase inhibitors are known to cause significant bone loss leading to
possible osteoporosis, as well as increase the risk of heart attacks, heart failures, and depression
8
Model Cell System
The cell line MCF-7 has been used as a model system for estrogen responsive breast cancer for
decades. As an estrogen responsive cell line, they test positive for the presence of the two types
of estrogen receptors, α and β. When estrogen binds to these receptors proliferative activity is
induced.
breast cancer. The cells were grown maintained for three years using radio and hormone therapy
before a pleural effusion was sampled and tested. Further cytogenic studies showed that their cell
line contained 88 chromosomes. Lippman found that when the MCF-7 cells were treated with
tamoxifen, an antiestrogenic drug, their growth was inhibited (Levenson, 1997). Exposure to the
hormone, estrogen, however, reversed the inhibition and the cells were once again able to
proliferate. Until this point, the drug had been classified as a competitive estrogen inhibitor,
which at high concentrations, was fatal to the cells. Dr. Lippman knew that his discovery aligned
with this classification and he announced his belief that, “The potential value of a hormone-
dependent human breast cancer in long term tissue culture for the study of mechanism(s) by
which steroid hormones exert their trophic effects is significant, particularly in view of the
(Levenson, 1997).
Over the next several years, many other discoveries regarding the MCF-7 cell line were made
including the identification of several different hormone receptors within the cells by Horwitz
(Levenson, 1977). Making MCF-7 cells a model system for tumor response mechanisms and
9
The MCF-7 cell line was a pivotal part in developing an understanding many aspects of breast
cancer cells. Study of this cell line has revealed the organization of the ER and steroid hormone
systems with breast cancer cells as well the effect of estrogen and antiestrogen on receptors.
Information gathered from the studies of these cells has also contributed towards the progress of
Estrogen
Estrogen is often referred to as the female sex hormone and is responsible for the development
and regulation of sex characteristics. In addition, it regulates the female reproductive system and
promotes growth and differentiation of the mammary glands. Estrogen is classified as a steroid
hormone and is able to readily diffuse across cell membranes. The most common type of
estrogen produced within the cell is 17β-estradiol. Once the estrogen molecules have crossed the
cell membrane, they can bind to estrogen receptors, which control a variety of gene expressions.
Estrogen levels in women are constantly fluctuating, even after puberty, due to their menstrual
Estrogen Receptor-α
Estrogen Receptor (ER) α is one of the two forms of estrogen receptors encoded by the ESR1
gene. Estrogen has been recognized as a vital factor for growth in a large number of breast
cancer cases. The presence of ER α has shown a direct correlation with positive prognosis (Ali,
2000). There is an overexpression of ER α in over 50% of all breast cancer cases. Of these cases,
70% respond to tamoxifen which is known to block ER α. In addition, a higher level of estrogen
receptor α indicates an increased risk for breast cancer. A large portion of breast cancer cases, in
which ER α is overexpressed, show a link between cell proliferation and estrogen binding to ER
α (Ali, 2000). Treatment of the breast cancer tumor cells through hormone therapy causes a
10
resistance to develop. To combat this resistance, diverse hormonal therapies are constantly being
Estrogen Receptor-β
Estrogen Receptor (ER) β is the second form of estrogen receptor, identified several years after
ER α (Hayashi, 2003). ER β presence has been detected in breast cancer tumor cells, especially
when they tested positive for ER α. ER β has been found to support growth and proliferation in
over 50% of primary breast cancers (Palmieri, 2002). When ER β was initially discovered in
1996, there were doubts of its importance in breast cancer. Further research has led to our current
understanding that both estrogen receptors have distinct cellular distribution. Both receptors
regulate separate genes and sometimes work against one another. ER β, when expressed in breast
cancer cells, can cause proliferation independent of ER α activation (Palmieri, 2002). When
treating breast cancer it is vital that treatment accounts for both receptors if they are expressed in
the cells.
recent years its function as an antimalarial agent has been further investigated, as well as any
other medicinal properties it may possess. Special attention has been paid to determining the
most potent form in which the plant can be administered in order to treat malaria. Additionally,
further research of the plant has shown the plant may potentially kill cancer cells and behave as
throughout the world. Medicinal use of the plant, known as “quighao” in traditional Chinese
11
medicine, dates back to 200 BC. It was believed that the cool (yin) of the herb would be
beneficial in treating internal sources of heat (yang) such as fevers. In 1596, it was first
suggested that tea made of Artemisia annua could be used to treat malaria. The modern study of
the plant began in the 1960’s when the Chinese government was searching for a new form of
antimalarial. The researchers attempted to follow the guidelines of the original treatment
protocol using hot water extracts of A. annua. They found that in this form, the plant had no
antimalarial effect on mice infected with the rodent malarial parasite, Plasmodium berghei. They
then treated the infected mice with cold ethereal extracts of A. annua. This method of extraction
In 1971, scientists began clinical trials on the use of extracted A. annua as an antimalarial for
primates infected with the Plasmodium parasite (Brown, 2006). Chinese military personnel
infected with the parasite were the first humans to be successfully treated with the extract. The
trial produced extremely positive results. The majority of patients in the trial received therapeutic
results and there did not appear to be any dangerous side effects to the treatment. Additionally,
the extract was found to effectively treat both chloroquine-resistant falciparum malaria and
cerebral malaria. Following the promising results of the cold ethereal extractions, the compound
artemisinin, the active ingredient in the A. annua plant, was isolated and identified in 1972
(Brown, 2006).
The compound, artemisinin, was found to contain a 1,2,4-trioxane ring. It is the only naturally
of many types of malaria. They have been found to rapidly eliminate malaria parasites with a
12
reduction ratio of roughly 10,000 per erythrocytic cycle. The source of artemisinin’s antimalarial
properties is the endoperoxide bridge in the compound’s trioxane structure. Though it has still
not been confirmed, the most likely mechanism of action for artemisinin’s treatment of malaria
involves the decomposition of the endoperoxide bridge upon interaction with heme, a non-
protein constituent of hemoglobin found within the parasite. The breakdown of the endoperoxide
bridge releases carbon-centered free radicals which then likely kill the parasite by destroying
essential malarial proteins. Artemisinin’s unique mechanism of action has even allowed
One reason that artemisinin’s mechanism of action is debated stems from the discovery that the
compound is also effective in cases of other parasitic infections, such as tick-borne Babesia
parasites. These parasites do not digest hemoglobin and therefore do not produce the heme
responsible for the decomposition of artemisinin’s endoperoxide bridge. This finding suggests
that this mechanism of action is not responsible for the anti-parasitic properties of artemisinin.
Instead, the efficacy of artemisinin treatment in these cases suggests the hypothesis that the
sarco/endoplasmic reticulum um ATPases, SERCAs, found in these parasites are the main targets
of artemisinin.
drug and radiation resistant (Amir, 2015). Cancer cells typically uptake larger amounts of iron
than healthy cells in order to proliferate. Artemisinin reacts with iron to form free radicals which
cause cell death. The increased iron uptake of cancer cells leaves them susceptible to the free
radicals artemisinin creates (Lai, 2005). Many cancer cells have a larger percentage of transferrin
receptors on the cell surface. These receptors increase uptake of the iron carrying protein
13
transferrin via endocytosis. When artemisinin covalently bonds to transferrin, both are taken into
the cell together. Once endocytosed, the artemisinin reacts with the iron, killing the cancer cells.
Artemisinin and transferrin bonded to artemisinin have been found to be extremely potent and
selective in causing cancer cell death (Lai, 2005). It is hypothesized that artemisinin’s anti
proliferative properties in cancer cell lines originates with artemisinin’s interactions with iron
and heme intermediaries (Zhang, 2009). Artemisinin has also been found to suppress vascular
endothelial growth factor C in lung cancer, increase calcium levels and activate p38 in lung cells,
of estrogen receptors (E2 and ER-β). Early testing of MCF-7 cells with artemisinin, an
antimalarial agent, demonstrates its ability to block estrogen induced cell progression and
proliferation. Sundars et al demonstrated that artemisinin blocked the proliferation of cells teated
Further research has shown that artemisinin dimers synthesized with liposomal nanoparticles
demonstrate improved anti proliferative effects. These nanoparticles become more water soluble
as the surrounding pH decreases, as tumors typically have a more acidic environment (Zhang,
2013). This improved delivery of artemisinin shows a down regulation of the HER2 protein in
HER2+ cell lines. The dimer has also been shown to decrease the growth factor receptor activity
in triple negative breast cancer, a notoriously hard types to treat through hormone therapy
(Zhang, 2013). This research further demonstrates the potential potency of the treatment options
14
Introduction
Breast cancer is the most common type of cancer present in women. There are over 203,000 new
diagnoses and more than 45,000 deaths associated with breast cancer every year. Over 70% of
breast cancer cell samples test positive for estrogen responsiveness. The cells’ responsiveness to
hormones determines the best treatment plan for the patient. Traditional methods of treatment for
Artemisia annua is a form of wormwood plant found throughout the world. The species naturally
produces a compound called artemisinin, which, for centuries, has been known to have
antimalarial properties (Brown, 2015). Recently, these properties have been investigated much
further (Brown, 2015). New research has suggested that the natural artemisinin compound may
Hundreds of years ago, the leaves of the artemisinin plant were consumed in the form of a tea as
a primitive treatment for malaria. Recent studies have shown that the plant is an effective malaria
treatment when made into pill form (Gogtay, 2013). Gogtay found that artemisinin is an effective
alternative to treating chloroquine resistant strains of malaria. This lead researchers to believe
that there are other compounds at work in the plant, whose potency is greatly reduced when
made into a tea. Another study found that when brewed in a tea, artemisinin flavonoids casticin
and artemetin were found at a 40% and 0% yield, respectively (Weathers et. al., 2012). These
compounds are likely responsible for the compound’s efficacy in the treatment of several forms
of cancer (Weathers et. al., 2012). Artemisinin has been shown to possess strong antagonistic
behavior towards estrogen receptor α (Sundar, 2008). Artemisinin not only blocks estrogen
receptor α, it also possesses strong cytotoxic traits (Shahbazfar, 20104). Artemisinin’s interaction
15
with iron, a substance taken in by cancer cells in large quantities, creates free radicals which kill
For patients with hormone responsive breast cancer, the typical treatment protocol is surgery
followed by, usually, around 5 years of hormone and combined drug therapy. Tamoxifen is the
most typical drug used to treat breast cancer. While tamoxifen is ineffective in its base form,
onceit is digested by the liver into afimoxifene and endoxifenits, affinity for estrogen receptor α
increases by more than 50 times (Henderson, 2003). This high affinity makes it a great
antagonist for the receptor. Some of the other hormones and drug treatments include
inhibitors (Hormone Therapy for Breast Cancer, 2012). These therapies are designed to target the
estrogen cycle in the body, specifically the production of the hormone or the estrogen receptors.
While drug and hormone therapies are effective against estrogen responsive breast cancer they
are not without side serious effects. Common side effects include heart problems, increased risk
of uterine cancer, increased risk of osteoporosis, mood swings, depression, fertility issues, etc
(Shahbazfar, 2014).
Hormone therapy also presents the risk of creating a treatment resistant strain of breast cancer.
To prevent development of a hormone resistant strain of breast cancer the treatments are
typically composed of several types of treatments that work in concert in method known as
combination therapy. Combination therapy treats the patient with a combination of drugs to help
prevent resistant strains from developing. Artemisinin is being studied as the base for a
combination therapy to help better prevent drug resistance (Gogtay, 2013). The inclusion of
artemisinin in the arsenal of treatments available to combat hormone responsive breast cancer
cell lines would help to reduce the risk of treatment resistant strains of breast cancer developing.
16
Treatment with the compound has also been shown to lack the negative side effects that
The use of artemisinin as a treatment option is still being studied (Suberu, 2014). While the
benefits have already become clear, there are many aspects of the compound that are still
unknown such as the exact method of action that gives the plant its anti-proliferative properties.
We hypothesize that the extract of artemisinin will contain compounds that will increase the
plant’s anti-proliferative abilities to be more effective than purified forms of the extract. This
hypothesis is based on the research into its antimalarial abilities have shown that raw forms of
17
Methodology
Cell Culture: MCF-7 Cell Line
MCF-7 ATCC cells were cultured according to the procedures outlined in (Hamelers, 2003).
Briefly, the cells were cultured in Dulbecco’s modified Eagle’s medium which contained 10%
fetal bovine serum (FBS) and 100 μg/ml of bovine insulin, 100 IU/ml of penicillin and 100
μg/ml of streptomycin. The cells were maintained at 370C. until they reached 60-70%
confluence. After plating at 103 cells/well in 96 well culture plates, the cells were incubated in
phenol red-free medium with 5% dextran-coated charcoal-treated (DCC) serum for 24 hours
followed by another 24 hours in phenol red-free, DCC serum stripped media containing 0.2%
Extraction
Extractions were performed following procedures outlined in Cambra (2014). 75 mg. of pre-
dried and crushed Artemesia annua leaves were placed in a 15 mL conical tube and 4 mL of
methanol was added to the tube. The tube was placed in an ultrasonic bath for 30 minutes on the
highest setting. The organic matter was then removed from the solution via filtration with filter
paper. The remaining methanol was left to evaporate under nitrogen. Following the nitrogen
mg/mL.
18
High Pressure Liquid Chromatography
HPLC was performed according to the procedure outlined in Ferreira (2008). An Agilent 1100
Series system HPLC with ultraviolet detection scanning from 190-400 nm was used. A C-18
column was run under isocratic conditions using a 40% 0.1% aqueous acetic acid/60%
acetonitrile mobile phase at a flow rate of 1 ml/min. Ethanol , pure artemisinin in ethanol, sample
plant extract in ethanol, and an extract sample spiked with pure artemisinin extract in ethanol
were analyzed. Between sample injections, the mobile phase was run alone for 5 minutes. The
data collection window was 15 minutes. The artemisinin peak in the extracted sample was
identified by elution time (Ferreira, 2008) and confirmed by spiking the samples with purified
compound.
performed using purified artemisinin as the standard. Four dilutions of the pure artemisinin
sample (1:10, 1:20, 1:30, and 1:40) were created and then run through the HPLC. The
concentrations (0.5 mg/ml, 0.25 mg/ml, 0.166 mg/ml, and 0.125 mg/ml) were plotted versus the
area under the artemisinin peak. A line of best fit was added to the graph and the line’s equation
was used to solve for the concentration of artemisinin in the plant extract sample, using the area
under the artemisinin peak of the sample. Since the sample was originally suspended in 10 mL
and the mass used in the extraction was 150 mg, it was possible to determine the artemisinin
MTT Assay
A Promega CellTiter 96 Non-Radioactive cell Proliferation Assay (MTT) was run to analyze the
effects of different concentrations of artemisinin, both pure and extract samples, as well as the
effects of estrogen on cell proliferation. Each sample was run in triplicate. The different wells
19
contained 1x103 cells and 10µL of the sample solution and were incubated for 48 hours in the
experimental condition solutions before 10µL of assay buffer was added to each well. After
adding the assay buffer, the plate was left to incubate for three hours and then read with a Biotek
EL800 plate reader at 450 nm. The conditions tested were: ethanol, 300 μM artemisinin, 300 μM
artemisinin combined with 1nM estrogen, 1nM estrogen alone, 30 μM pure artemisinin, 30μM
pure artemisinin, 300 μM pure artemisinin and estrogen, 30μM pure artemisinin and estrogen,
300μM extract sample of artemisinin, 300μM extract sample of artemisinin and 1nM estrogen,
ethanol and 1nM estrogen, 30 nM extract sample of artemisinin, 30μM extract sample of
artemisinin, and 30 μM extract sample artemisinin and 1nM estrogen. There were also wells
containing only media and a blank well containing only cells and media. Once the absorbances
were determined, the value for wells plated without cells (media only), was subtracted from the
absorbance of each well to ensure that the cell metabolism and overall cell amount were
accurately measured. The results between the different plates were then averaged. To eliminate
interplate variability, a percent control was calculated by dividing the average readings for each
sample by the average readings for the untreated control and multiplying by 100.
20
Results
HPLC
High performance liquid chromatography (HPLC) was used to confirm and quantify artemisinin
To identify peaks which result from absorbance by the solvent, ethanol, a solvent only control
Ethanol
Figure 1 shows the peak elution time at 3.1 minutes for 70% aqueous ethanol.
The chromatogram for the pure artemisinin sample at a concentration of 5 mg/ml of artemisinin
21
Artemisinin
Figure 2 shows two major peaks at 3.1 and 5.1 minutes. As the peak at 3.1 minutes was
previously identified as ethanol, the peak at 5.1 minutes falls at the predicted elution time for
artemisinin according to previous research (Ferreira, 2008). The area under the peak was
Next, an HPLC of sample extract from the dried plant matter was run and the results are shown
below in Figure 3.
Artemisinin
22
The chromatogram in Figure 3 showed the expected peaks for ethanol at 3.1 minutes and a peak
eluted at 5.1 minutes, conditionally identified as artemisinin with an area of 257 mAu*s. To
verify the identity of this peak as artemisinin, the sample solution was spiked with pure
artemisinin at a 1:1 ratio. The results of the spiked extract can be seen in Figure 4, below.
Artemisinin
Figure 4 shows the chromatogram of the spiked extract in which the peak located at 5.1 minutes
went from an area of 257 mAu*s to 3,488 mAu*s. The spiked sample demonstrates that the
compound eluted at 5.1 minutes was definitely artemisinin. Once the identification of artemisinin
was confirmed, the amount of artemisinin in the sample extract needed to be compared to the
pure sample to control the amount of artemisinin the cells were treated with.
Once the artemisinin peak in the sample was successfully identified, the total artemisinin content
was determined as details in Methods. An HPLC was run on four different dilutions of pure
artemisinin (1:20, 1:30, and 1:40). The chromatograms of the dilutions are shown in Figures 5, 6,
and 7, below.
23
Figure 5: Chromatogram of 1:20 Dilution
The peak area of artemisinin at 0.25 mg/ml, shown above in Figure 5, was found to be 308
mAu*s.
The peak area of artemisinin at 0.166 mg/ml, shown above in Figure 6, was found to be 201
mAu*s.
24
Figure 7: Chromatogram of 1:40 Dilution
The peak area of artemisinin at 0.166 mg/ml, shown above in Figure 7, was found to be 183
mAu*s. With this data, the area versus the concentration of the sample was plotted. The linear
Linear Regression
350
300
y = 1042.4x + 42.361
HPLC area mAu*s
250
0.25 mg/mL
200
0.166 mg/mL
150
0.125 mg/mL
100
Dilutions
50
Linear (Dilutions)
0
0 0.1 0.2 0.3
Concentration (mg/mL)
In Figure 8, a line of best fit for area versus known concentration of artemisinin was determined.
Using this line of best fit and the area under the artemisinin peak for the sample (257 mAu*s) as
25
the y value, it was possible to solve for the artemisinin concentration (x value) in the sample
plant extract. This value was determined to be 0.2083 mg/ml in the sample, which was initially
suspended in 10 ml of ethanol. From the 150 mg of Artemisia used to produce the sample
extract, 1.4% artemisinin was extracted . Once this was determined, it was possible to control the
amount of artemisinin the cell treated with the plant extract received.
MTT Assay
Each well was initially plated with 103 cells and after cell synchronization they were treated with
several different experimental conditions. The control group (None) received no extra
compounds. Ethanol, at a concentration of <1% (Ethanol or EtOH), was used to treat another
group. The pure artemisinin (Pure Art or P) solution, dissolved in aqueous ethanol, was used to
treat the cells at 300 μM. The sample extract solution (Sample or S) was also used to treat the
cells at 300 μM. A 1:10 dilution of both artemisinin samples were also used as conditions (30
μM). All of the conditions were repeated with the addition of estradiol (E2) at 2 ng/ml. A set of
control wells was also set up where media was added without the cells. The conditions were
tested in triplicate for each 96 well plate. The organization of the conditions in the 96 well plates
26
Table 1: MTT Assay Results Key
1 2 3 4 5 6 7 8 9 10 11 12
A None None None S+E2 Media Only
CellTiter administration. Original data for each experiment can be found in Appendix.
Table 2 shows the absorbance readings of the first plate, read at 450 nm. Once another plate was
ready for assaying, the one step assay solution was applied and the plate was incubated for an
additional 3 hours before being read. The results found in Table 3 were, as a whole; lower than
the ones of the previous assay. Possible reasons for the lowered value include cell count not
being as high in the previous assay, despite efforts to control cell number, or lower cell viability
when added to the plate. The absorbance values in the third plate, shown in Table 4, were not as
low as the ones observed in Table 3 and bore more similarity to the values initially observed in
Table 2
Individual plate readings were adjusted by subtracting the value for the no cell blank for each
plate. Then the average for each condition was determined (plate 1, 2, and 3) for each
experiment and finally the average for each condition across three experiments was calculated
(Ave). Each value was then expressed as 5 control with the no treatment control set at 100%.
27
Table 2: MTT Assay Averages (Adjusted for Media)
0.3
Ethanol
0.25
Pure
0.2
Sample
0.15
10% S
0.1
0.05 10% Pure
0
Conditions
Figure 9 shows a graphic representation of the absorbance values shown in Table 2 for the
samples in which no estrogen was present. The data for samples to which estrogen was added are
28
shown in Figure 10. The interplate variability among experiments resulted in large statistical
Estrogen Conditions
0.6
0.5
None
Absorbance (Au)
0.4 Ethanol
0.3 EtOH+E2
E2
0.2
S+E2
0.1
P+E2
0
Conditions
To help limit its effects on the results, a percent control of the results shown in Table 2 was
calculated by comparing all the conditions to the control average. These data are shown in Table
29
Percent Control
250
Ethanol
Relation to Control (%) 200 Pure
Sample
150
10% S
10% P.A.
100
E2
50 EtOH+E2
P+E2
0 S+E2
Condition
Examination of the percent controls shows two distinctly different results for the ethanol with
estrogen condition and the pure artemisinin with estrogen condition. The ethanol and estrogen
condition had a percent control value of 160% while the pure artemisinin with estrogen had a
percent control value of 81%. The pure artemisinin value is the only one below 100% with all
other conditions at percent controls above 100% as shown in Table 5 and Figure 11. A t-test of
the values for estrogen plus ethanol and artemisinin plus ethanol shows a p-value of 0.28,
however, which is not enough to prove statistical significance of these results. However, the
other outcome worth noting is that the extract sample, which has the equivalent amount of
artemisinin, does not appear to have an equivalent effect to the pure compound.
30
Discussion
From the MTT assay results it has not been possible to show that the pure artemisinin has a
significantly greater effect on MCF-7 cell growth than the sample extracts, directly from the
Artemesia annua plant, with other compounds present. Unfortunately we have also not been able
the data were statistically significant they do suggest that there could be an effect if more trials
were conducted and the sample size was increased to more than the three plates performed in this
study. While no strong trends were found in the average of the plate results shown in Figure 9
and Figure 10, there are some observable trends found in the percent control data shown in
When viewed as percent control, it appeared that there was a lower cell number when the cells
were treated with the pure artemisinin and estrogen as compared to the ethanol and estrogen
condition with no artemisinin present. With ethanol concentration kept below 1%, its toxic
effects on the cells was shown to be negligible, suggesting that the estrogen and ethanol
condition’s high percent control value (160% ) is likely should be due solely to the estrogen
presence. The pure artemisinin with estrogen had a percent control value of 81%, while the other
conditions were all over 100% in the percent control calculations, shown in Table 6.
With any antiproliferative effect limited to the pure sample with estrogen, the prediction that
artemisinin acts as an estrogen receptor antagonist is supported (Sundar, 2008). The same effect
was not observed with the sample extract of the plant Artemisia annua. Since the artemisinin
amount was controlled, this suggests that there may be other compounds in the sample extract
that have either agonistic behaviors or prevent the artemisinin from acting as an antagonist. If ,
31
with further validation, this result persists it may suggest that any use of the Artemisia annua
plant in a form that is not pure, for treatment of estrogen responsive breast cancer, would be
useless, if not possibly detrimental, to the patient. While our initial expectations were that there
might be other compounds in the plant which would act synergistically to support the anti-
proliferative effects of artemisinin, unlike what has been shown for treatment of malaria, this
does not appear to be the case. Furthermore, the use of Artemisia annua to treat non-estrogen
responsive cancer would have either no effect or a positive effect on breast cancer cell
proliferation. Clearly more work needs to be done before these conclusions can be validated.
Future Recommendations
Future teams will first want perform a dose responsiveness curve for artemisinin and its effects
on the cells. This will help future teams confirm that they are treating the cells with the
groups will want to replicate any artemisinin responsiveness in the cells before proceeding and
expanding the experiment. Future research will want to monitor responsiveness of the cells with
an MTT assay at different time intervals, rather than just the 48 hours used in this experiment as
an incubation time. This will help any future researchers determine the optimal time frame in
which the artemisinin effects on the cells are observable. It is also possible an MTT assay may
not be a sensitive enough assay to monitor cell proliferation if the artemisinin effect is not as
In the future, research can be expanded to use different cultivars of artemisinin to determine if
the effect is unique to each batch of artemisinin. Future research can also examine the effects of
digested artemisinin on the cancer cells. Any further research will want to isolate the compounds
present in the artemisinin extracted from the plant that were not found in the pure sample and
32
attempt to determine the individual effects each compound may have on the cells. Additionally,
though this experiment plated 103 cells in each well, it may not have been the optimal number to
use so any future research will first want to determine the appropriate amount of cells needed in
repetitions of the experiment will be required in order to produce any meaningful and statistically
significant data. Several plates of data were lost due to error in following experimental
procedure. Maintaining consistency in cell plating between wells is also extremely difficult,
despite careful cell counting and resuspension procedures. While multiple forms of research
literature were used to determine the correct artemisinin concentration to treat the cells with, it
was not necessarily the optimal amount to use on the cells. Determining the best concentrations
to use may yield stronger results. While these results did not produce any statistically significant
findings, they did suggest further research is warranted to determine and prove the difference in
the effects of pure artemisinin and an extract taken directly from plant samples. Further research
will help demonstrate which forms of artemisinin can be a viable treatment for breast cancer and
if using raw extracts taken from the plant will actually harm a patient.
33
References
Ali S, Coombes RC. Estrogen receptor alpha in human breast cancer: occurrence
and significance. J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):271-81. Review.
PubMed PMID: 14973389.
Amir Gharib, Zohreh Faezizadeh, Seyed Ali Reza Mesbah-Namin, and Ramin Saravani.
Experimental treatment of breast cancer-bearing BALB/c mice by artemisinin and transferrin-
loaded magnetic nanoliposomes PMCID: PMC4461950
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461950/
Brown, Geoff. "Artemisinin and a New Generation of Antimalarial Drugs." Royal Society of
Chemistry. N.p., 2006. Web. 06 Oct. 2015.
<http://www.rsc.org/Education/EiC/issues/2006July/Artemisinin.asp>.
Cambra, Hailey. “TLC Fingerprinting: Artemisia annua.” Worcester Polytechnic Institute. 2013
April, 23. Nov 12 2015.
Dadgar N, Alavi SE, Esfahani MK, Akbarzadeh A. Study of toxicity effect of pegylated
nanoliposomal artemisinin on breast cancer cell line PMCID: PMC3783905
http://www.ncbi.nlm.nih.gov/pubmed/24426245
Etymologia: Artemisinin. Emerg Infect Dis [Internet]. 2014 Jul [2015 Oct. 6].
http://wwwnc.cdc.gov/eid/article/20/7/et-2007_article
Ferreira, J., Gonzalez, J. (2008). Analysis of underivatized artemisinin and related sesquiterpene
lactones by high-performance liquid chromatography with ultraviolet detection.
Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. Artemisinin‐based combination therapy
for treating uncomplicated Plasmodium vivaxmalaria. Cochrane Database of Systematic Reviews
2013, Issue 10. Art. No.: CD008492. DOI: 10.1002/14651858.CD008492.pub3
34
Hayashi, S., Eguchi, H., Yoshida, T., & Inoue, A. (2003). The expression and function of
estrogen receptor and in human breast cancer and its clinical application.International Congress
on Hormonal Steroids and Hormones and Cancer, 1(10), 193-202. Retrieved October 8, 2015,
from http://erc.endocrinology-journals.org/content/10/2/193.long
Henderson BE, Bernstein L, Ross RK. Breast Cancer. In: Kufe DW, Pollock RE, Weichselbaum
RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.
Available from: http://www.ncbi.nlm.nih.gov/books/NBK13155/
Holliday, D. (2011) Choosing the Right Cell Line for Breast Cancer Research.
Hormone Therapy for Breast Cancer. (2012, August 2). Retrieved October 3, 2015.
http://www.cancer.gov/types/breast/breast-hormone-therapy-fact-sheet
John O Suberu, Isolda Romero-Canelón, Neil Sullivan, Alexei A Lapkin, Guy C Barker.
Comparative Cytotoxicity of Artemisinin and Cisplatin and Their Interactions with Chlorogenic
Acids in MCF7 Breast Cancer Cells. ChemMedChem. 2014 December; 9(12): 2791–2797.
Published online 2014 September 10. doi: 10.1002/cmdc.201402285. PMCID: PMC4506560
Lai H, Sasaki T, Singh NP. Targeted treatment of cancer with artemisinin and artemisinin-tagged
iron-carrying compounds. Expert Opin Ther Targets. 2005 Oct;9(5):995-1007. Review. PubMed
PMID: 16185154.
Levenson, A., & Jordan, V. (1997). MCF-7: The First Hormone-responsive Breast Cancer Cell
Line. Perspectives in Cancer Research, 1(57), 3071-3078.
35
Ovarian Ablation for Women With Early-Stage Breast Cancer. (2011, September 6). Retrieved
October 3, 2015. http://www.cancer.net/research-and-advocacy/asco-care-and-treatment-
recommendations-patients/ovarian-ablation-women-early-stage-breast-cancer
Qaderi A, Dadgar N, Mansouri H, Alavi SE, Esfahani MK, Akbarzadeh A. Modeling and
prediction of cytotoxicity of artemisinin for treatment of the breast cancer by using artificial
neural networks PMCID: PMC3727081 http://www.ncbi.nlm.nih.gov/pubmed/23961405
Shiming Zhang, Glenn S. Gerhard. Heme Mediates Cytotoxicity from Artemisinin and Serves as
a General Anti-Proliferation Target PLoS One. 2009; 4(10): e7472. Published online 2009
October 28. doi: 10.1371/journal.pone.0007472. PMCID: PMC2764339
Shyam N. Sundar, Crystal N. Marconett, Victor B. Doan, Jamin A. Willoughby, Sr, Gary L.
Firestone. Artemisinin selectively decreases functional levels of estrogen receptor-alpha and
ablates estrogen-induced proliferation in human breast cancer cells Carcinogenesis. 2008
December; 29(12): 2252–2258. Published online 2008 September 10. doi:
10.1093/carcin/bgn214. PMCID: PMC2639250
Singh, N., Ferreira, J., Park, J., & Lai, H. (2011). Cytotoxicity of Ethanolic Extracts of Artemisia
annua to Molt-4 Human Leukemia Cells. Planta Med Planta Medica, 1788-1793.
36
Weathers PJ, Towler MJ (2012). The flavonoids casticin and artemetin are poorly extracted and
are unstable in an Artemisia annua tea infusion. Plant Med 78: 1024-1026.
Yitong J. Zhang, Byron Gallis, Michio Taya, Shusheng Wang, Rodney J. Y. Ho, Tomikazu
Sasaki. pH-Responsive Artemisinin Derivatives and Lipid Nanoparticle Formulations Inhibit
Growth of Breast Cancer Cells In Vitro and Induce Down-Regulation of HER Family Members.
PLoS One. 2013; 8(3): e59086. Published online 2013 March 14. Doi:
10.1371/journal.pone.0059086. PMCID: PMC3597601
37
Appendix
Table 3: MTT Assay Plate 1
Plate
1 2 3 4 5 6 7 8 9 10 11 12
1
A 0.596 0.599 0.442 0.25 0.038 0.039 0.039 0.038 0.043 0.039 0.039 0.219
B 0.592 0.384 0.711 0.691 0.039 0.04 0.04 0.04 0.04 0.039 0.04 0.228
C 0.434 0.747 0.774 0.718 0.041 0.041 0.04 0.04 0.039 0.039 0.043 0.042
D 0.607 0.724 0.717 0.458 0.04 0.045 0.04 0.043 0.042 0.041 0.044 0.04
E 0.508 0.685 0.382 0.318 0.816 0.04 0.043 0.04 0.041 0.041 0.042 0.042
F 0.336 0.556 0.621 0.377 0.83 0.04 0.039 0.043 0.04 0.052 0.04 0.042
G 0.561 0.602 0.637 0.63 0.737 0.041 0.04 0.041 0.043 0.041 0.044 0.044
H 0.608 0.626 0.425 0.603 0.498 0.039 0.04 0.039 0.04 0.041 0.04 0.041
Plate
1 2 3 4 5 6 7 8 9 10 11 12
2
0.24 0.26 0.25 0.27 0.03 0.03 0.03 0.03 0.04 0.03
A 0.23
3 8 7 2 8 9 8 8 1 8
0.16
0.25 0.24 0.25 0.28 0.26 0.04 0.03 0.03 0.03 0.03 0.04
B 1 7 8 5 5 7 8 9 8 9 1
0.17
0.20 0.24 0.26 0.26 0.25 0.03 0.03 0.03 0.03 0.04
C 0.04 0.04
9 7 2 8 9 9 8 8 8 2
0.23 0.24 0.27 0.29 0.25 0.03 0.03 0.04 0.04
D 6 8 7 1 2
0.04
9
0.04
9 2
0.04
1
0.24 0.28 0.26 0.03 0.03 0.04 0.04 0.03 0.03
E 4
0.26
6 8 9
0.04
9
0.04
1 2 9 9
0.24 0.17 0.28 0.29 0.03 0.04 0.04 0.04 0.04 0.04
F 6 8 3 2 9
0.04 0.04
1 3 1 2 2
0.23 0.28 0.27 0.26 0.03 0.03 0.04 0.04 0.04 0.04
G 5 4 6 7 9 8
0.04 0.04
2 2 3 5
0.23 0.23 0.28 0.25 0.03 0.03 0.03 0.03 0.04 0.04 0.04
H 5 5 9 5 9 9
0.04
8 9 4 3 4
38
Table 5: MTT Assay Plate 3
Plate
1 2 3 4 5 6 7 8 9 10 11 12
3
A 0.494 0.475 0.473 0.557 0.039 0.039 0.039 0.038 0.044 0.039 0.044 0.188
B 0.532 0.527 0.536 0.562 0.041 0.04 0.039 0.04 0.04 0.039 0.04 0.196
C 0.543 0.555 0.563 0.531 0.041 0.041 0.04 0.04 0.039 0.041 0.043 0.042
D 0.607 0.511 0.531 0.435 0.04 0.045 0.044 0.044 0.042 0.041 0.044 0.04
E 0.508 0.685 0.382 0.424 0.649 0.04 0.041 0.044 0.041 0.041 0.04 0.039
F 0.656 0.621 0.588 0.431 0.653 0.04 0.039 0.043 0.044 0.039 0.04 0.042
G 0.64 0.597 0.601 0.525 0.657 0.041 0.04 0.041 0.043 0.041 0.044 0.044
H 0.701 0.554 0.34 0.503 0.512 0.039 0.04 0.039 0.04 0.041 0.04 0.041
39